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Objective. To evaluate a new Hyaluronan-based graft.
Material and methods. Hyaluronan-based grafts (HYAFF 11 tube, diameter 2 mm, length 1.5 cm) were implanted in
an end-to-end fashion in the abdominal aorta of 15 rats. Histology, immunohistochemistry and electron microscopy were
used to evaluate the results at 7, 21, and 90 days.
Results. At day 7, new tissue was observed in the graft coming from both the proximal and distal ends of the aorta. The
luminal surface of the regenerating tissue was covered by endothelial cells (CD34þ, VEGFR-2þ, vWFþ). At day 21,
regenerating tissue joined at the centre of the tube. The neo-vessel was formed by smooth muscle cells (Myosin Light Chain
Kinase) as well as elastic, and collagen fibres. At day 90 a stable artery segment was formed and the biomaterial was almost
completely degraded. Infiltration of neutrophils and lymphocytes was not observed. All animals survived the observation
period and there were no signs of stenoses or aneurysms.
Conclusion. The hyaluronan-based graft allowed complete regeneration of a newly formed vascular tube in which all the
cellular and extracellular components are present and organized in a well defined architecture similar to native artery.
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Reconstruction of blood flow using an arterial substi-
tute is a common form of revascularisation. Native
conduits are often not available because of previous
surgery. The research of an alternative to native blood
vessels has primarily focused on bypass graft engi-
neered from synthetic material, e.g. Dacron or
expanded Polytetrafluoroethylene (ePTFE). Although
successful in large caliber, high flow vessels, pros-
thetic grafts have disappointing results in small, low
flow vessels.1
Creating an adequate small caliber vascular graft
has become one of the prime targets of tissue
engineering. An example is an endothelial cell (EC)-
seeded synthetic graft, however, only a few groups
have achieved clinical success with this technique.2
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shifted to developing a blood vessel substitute that
has all the functional characteristics of a normal blood
vessel. This engineered substitute should not only have
a nonthrombogenic surface but must also acquire ap-
propriate biomechanical properties matching those of
native vessels. For a small diameter blood vessel sub-
stitute full functionality cannot be achieved without
an EC-like interface, contractile smooth muscle cells
(SMCs) and an extracellular matrix made of collagen
and elastin that provide both strength and elasticity
to pulsatile blood pressure. Several approaches have
emerged in the last two decades: collagen based blood
vessel analogues,3 biodegradable synthetic polymer
based constructs,4 cell self assembly blood vessels,5
cell seeding of biodegradable scaffolds6 and decellular-
ized tissue approaches to blood vessel grafting.7
Taking advantage of the concepts gained from pre-
vious experience, we devised a new biological graft,
made of modified hyaluronan, a native component
of the extracellular tissue matrix, as a temporary
absorbable guide to promote the sequential and
complete regeneration of vascular structures at the
implantation site. The objective of this study was toved.
412 S. Lepidi et al.test a 2 mm diameter hyaluronan graft in a well estab-
lished rat aorta model.8,9
Materials and Methods
Vascular graft fabrication
The biomaterial, derived from total esterification of
hyaluronan (synthesized from 80e200 kDa sodium
hyaluronate) with benzyl alcohol and referred to as
HYAFF-11, was dissolved in DMSO. A core steel
rotating cylindrical bar, 2 mm in diameter, was coated
with 1.5 ml of the HYAFF-11/DMSO solution,
which was subsequently coagulated in an ethanol
bath. The shaped tubules were carefully removed
from the cylinder, cut to 2.0 cm in length and 2 mm
in diameter (50 mm thick), washed in water and air-
flow dried. They were then double blister packed and
sterilized by gamma-radiation. These HYAFF-11
tubules were a gift of Fidia Advanced Biopolymers
(Abano-Terme, Italy).
Surgical implantation of the prostheses
The protocol was approved by the Institutional
Animal Care Committee of Padova University. Fifteen
male Sprague Dawley rats weighing 250e350 grams
were used. Surgical procedures were performed with
the animals maintained under halothane anesthesia.
The abdominal area was shaven and aseptically pre-
pared using povidone-iodine (Betadine). The abdomi-
nal muscles were exposed with a 3-cm abdominal
incision. The aorta, from the renal arteries to the aortic
bifurcation, was exposed and isolated. After clamping
the vessel, a segment of aorta (1 cm) was excised and
the HYAFF 11 graft, 2 mm in diameter and 1.5 cm
in length, soaked in DMEM (Dulbecco Modified Eagle
Medium) at 4 C for 7 days, was anastomized first
proximally then distally in an end-to-end fashion
with continuous 10.0 polypropylene suture. No anti-
coagulants were used before or after the operation,
and no prophylactic antibiotic was administered. All
surgical procedures were performed in an identical
fashion by a single surgeon. The animals were fed an
unrestricted standard diet.
Graft explant
Five animals were sacrificed at each time point: 7, 21
and 90 days. Prior to sacrifice, rats underwent a gen-
eral physical examination to evaluate their condition.Eur J Vasc Endovasc Surg Vol 32, October 2006Anaesthesia was induced as described for implan-
tation. The prosthetic site was carefully exposed at
the point of previous surgical entry. Photographs and
videos were taken for gross observation. After clamp-
ing, the aorta was excised transversally, first distally
then proximally, 5 mm from the anastomosis. The har-
vested segments were rinsed carefully with heparin-
ized saline. Prostheses were cut transversally at the
midline in two pieces and fixed in formaldehyde
and in embedding medium for frozen tissue speci-
mens (O.C.T. Tissue-Tek) for histology, immuno-his-
tochemistry, and ultra-structural analyses. Some
samples were entirely formalin fixed or cryopreserved
and full longitudinal sections were obtained for rou-
tine staining. After graft harvesting, the animal was
killed with an overdose of barbiturates (Nembutal
sodium solution, Abbott Laboratories, USA).
Explant morphology
Sections of the explanted graft were stained with
haematoxylin-eosin (HE) and Weighert solution for
cells and elastin evaluation respectively. Immunofluo-
rescent studies of endothelial cells used antibodies
to von Willebrand factor (vWF) (DAKO, Carpenteria,
California), CD34 (Santa Cruz Biotechnology, Santa
Cruz, California), and Vascular Endothelial Growth
Factor Receptor-2 (VEGFR-2) (Santa Cruz Biotechnol-
ogy, Santa Cruz, California). To characterize vascular
smooth muscle cells, antibodies to Myosin Light Chain
Kinase (MLCK) was used according to the method de-
scribed by Giorgio Vescovo et al.10 Hoechst stain was
used for nuclear staining. Primary antibodies used to
detect the presence of collagens were anti-collagen I
(Sigma, Saint Louis, Missouri), anti-collagen III
(Chemicon International, Australia), and anti-collagen
VI (Calbiochem, Germany). Negative controls were
performed by replacing primary antibody with nor-
mal rabbit serum or phosphate-buffer salt solution.
Immune reactions were revealed by the Fast Red
Substrate (Sigma) (collagen I and III) and 3,3-
Diaminobenzidine (Sigma) (collagen VI), and counter-
stained with hematoxylin (Sigma). Moreover, samples
were processed for transmission electron microscopy
and examined using a Phillips EM400 microscope
(Eindhoven, The Netherlands).
Results
Gross observations at surgery and harvest
After 7 days in DMEM at 4 C, HYAFF 11 graft
(Fig. 1A) becomes soft, easy to cut and suture using
413Hyaluronan Biodegradable Scaffold for Small-caliber Artery GraftingFig. 1. Surgery. (A) HYAFF-11 (2 mm tube diameter) before grafting. HYAFF-11 graft (1.5 cm long) after proximal and
distal termino-terminal anastomoses with the infrarenal abdominal aorta, before (B) and after (C) release of vascular clamps.a 10.0 prolene stitch. The time required to complete
the two anastomoses was approximately 45 minutes.
When the clamps were removed and blood flow
resumed, bleeding from needle holes at the graft anas-
tomoses was easy to stop using collagen sponge
(TissuFleece E, Baxter, Nu¨rnberg, Germany) within
a few seconds. Fig. 1B and C illustrate the graft before
and after the release of vascular clamps at implanta-
tion. Pulsatile flow was visible in the proximal and
distal aorta after clamp release and maintained at sub-
sequent time points. Signs of thrombosis and infection
were never visible. Animal survival rate was 100%and no signs of peripheral vascular insufficiency
were observed in the hindlimbs. At day 7, the anasto-
moses were solid and well integrated with the origi-
nal artery, the graft was not dilated and through the
transparency of the HYAFF 11 tube, it was possible
to observe the growth of new arterial tissue (Fig. 2A).
At day 21, the original HYAFF 11 graft was not
visible because it was completely surrounded by
abundant connective tissue, giving the impression of
dilated vessel, although signs of aneurysmal dilation
were never observed in the developing neo-vessel
inside the graft, as shown by the microscopic analysisFig. 2. 7 Days after surgery. (A) Gross morphology after harvesting (stereomicroscope image, Olympus SZX 12-). Prolene
suture is visible at the anastomotic site and the developing new vascular tissue is clearly evident through the transparent
tube. (B) HE staining of longitudinal sections of the proximal artery and HYAFF graft: the biomaterial is clearly evident (red
arrow). Thin layers of newly formed tissue both on the luminal and external surface of the tube originate from anastomotic
site (black arrow). Immunostaining for muscle cells (MLCK) (C) and Weighert staining for elastic fibres (D) are confined to
the original artery tract and do not enter anastomotic sites (arrows in figure C and D mark the transition point between
original and new artery). Luminal surface of the prosthesis is lined by vWF (E) and CD34 (F) positive cells. CD34 positive
cells are confined to the neoartery tract and are negative in the original artery tract (E). White arrow in (E), and (F) marks the
transition point between original and new artery. Scale bar¼ 50 mm.Eur J Vasc Endovasc Surg Vol 32, October 2006
414 S. Lepidi et al.(see following sections). At day 90, the external con-
nective tissue was less abundant, many vasa-vasorum
were macroscopically visible on the outside surface of
the graft and the impression of a dilated vessel was
much less evident.
The 7th day: the endothelial lining was regenerated
Fig. 2B is a microscopic picture of the prosthesis seven
days after surgery. The biomaterial was clearly evi-
dent and maintained its structure (blue arrows in
Fig. 2B). Longitudinal sections revealed the presence
of a thin layer of newly formed tissue both on the lu-
minal and external surface of the graft. Regeneration
of neo-vascular tissue originated from both proximal
(black arrows in Fig. 2B) and distal anastomotic sites,
growing along the tube without any signs of infiltra-
tion into the graft wall. Simultaneously, an adventi-
tial-like tissue started to grow from the aorta onto
the external surface of the graft (Fig. 2B). The growing
new tissue was easily detached from the graft on
histology preparation. Cells were not observed inside
the hyaluronan tube. Fig. 2C and D illustrate the ab-
sence of a muscular and elastic component in the
neo-vessel at this time. Positive staining for vascular
smooth muscle cells and elastic fibres was confined
in the original artery tract (arrows in Fig. 2C,D). The
growing tissue on the luminal surface of the graft,
was layered by vWFþ (Fig. 2E) and VEGFR-2þ (data
not shown) endothelial cells (Fig. 2E,F) and by
CD34þ endothelial cell progenitors (Fig. 2F). In partic-
ular, the presence of CD34þ cells confirmed the partic-
ipation of circulating endothelial progenitor cells in
these early regenerative events. Positive staining for
CD34 was confined to the neo-artery tract and was
negative in the original artery tract (white arrow in
Fig. 2F marks the transition point between original
and new artery).
The 21st day: all artery components are present
Fig. 3A illustrates a longitudinal section of the pros-
thesis on day 21 after surgery. The biomaterial was
still present (red arrow), its structure intact, envelop-
ing the neo-vessel at this point with no signs of vascu-
lar tissue infiltration. Connective tissue surrounded
the biomaterial externally, resembling an adventitial
wall and isolating the biomaterial from the external
environment. Flattened cells were observed on the lu-
minal surface, with a basal membrane and an internal
elastic lamina which resembled a native intimal layer
as clearly illustrated by transmission electron micros-
copy (Fig. 3B). Vascular lumen was lined with cellsEur J Vasc Endovasc Surg Vol 32, October 2006that stained positively for vWF (Fig. 3C). Immuno-
fluorescence confirmed the presence of a continuous
thin layer of mature vascular smooth muscle cells
(Fig. 3D), as indicated by positive staining with an an-
tibody specific for myosin light chain kinase (MLCK).
Elastic components of the neo-artery wall progres-
sively started to regenerate from the anastomotic
site, as illustrated in Fig. 3F.
The 90th day: The new artery wall is fully developed
and the biomaterial is degraded
After ninety days, haematoxylin-eosin staining of
transverse sections (Fig. 4A) demonstrated a vascular
lumen of normal diameter, the neo-vessel developed
all the morphological components of a normal artery
and the HYAFF material degraded (Fig. 4B). Adventi-
tial tissue, which at previous time points enveloped
the prosthesis externally was now connected to the in-
ner layers developing inside the graft. Endothelial,
muscle, and elastic layers were complete, as respec-
tively shown in Fig. 4CeE. Positive staining for colla-
gens I, III and VI (data not shown) was easily visible
and for the most part confined to the adventitia.
Macrophages were present, however monocytes and
neutrophils were absent or scarcely visible (data not
shown).
Discussion
Hyaluronan, a glycosaminoglycan (GAG), is a major
constituent of the extracellular matrix in which most
tissues differentiate. Hyaluronan is present in all nor-
mal blood vessels in the intima and in the adventitia
with only a patchy distribution in the media. The
amount of hyaluronan depends on the type and age
of blood vessels. Hyaluronan ranges from 40% to 4%
of the total GAG content in the fetal umbilical artery
and the adult aorta respectively. The high content of
hyaluronan in fetal blood vessels creates a loose and
hydrated vascular ECM that provides them with flex-
ibility and also allows the vascular cells to move and
sort themselves into layers during the formation of ar-
teries and veins.11 The content of arterial hyaluronan
changes as the functional demands of the artery
change.12 Hyaluronan also accumulates at different
stages in atherosclerosis and restenosis.13e14
The biochemical properties of hyaluronan has
made this molecule very appealing for clinical appli-
cations. The hyaluronan used was isolated initially
from human umbilical cord, and shortly thereafter
from rooster combs in a highly purified and high
molecular weight form. The first medical application
415Hyaluronan Biodegradable Scaffold for Small-caliber Artery GraftingFig. 3. 21 days after surgery. (A) Longitudianl section of the prosthesis stained with HE. The biomaterial is intact and neo-
vascular tissue runs from distal to proximal anastomosis either on the luminal and external surface (White arrows point
anastomotic sites). (B) Transmission electron microscopic (Phillips EM400) magnification (12.000) of the neo-artery
luminal surface showing endothelial cells and a basal membrane. The neo-vascular lumen is lined with vWF positive
cells (C) and the Neo-vascular wall is populated by vascular smooth muscle cells, as evidenced by the immunostaining
for MLCK (D). The progressive formation of elastic component is evident after Weighert staining (F). Panel E shows the
nuclei staining (Hoechst). Scale bar¼ 1 mm.of hyaluronan for humans was as a vitreous supple-
ment/replacement during eye surgery in the late
1950s. The hyaluronan molecule is an attractive build-
ing block for new biocompatible and biodegradable
polymers that have applications in drug delivery, tis-
sue engineering, and viscosupplementation.
Modified hyaluronan biomaterials (HYAFF 11,
Fidia Advanced Biopolymers) have been prepared
and used as meshes and sponges for growth of cul-
tured human cells like fibroblasts and keratinocytes
for skin reconstruction15e16 and for culture of chon-
drocytes and bone-marrow derived mesenchymal cells
for repair of cartilage and bone defects.17e18 These
polymers show good mechanical strength.Recently, human vascular cells like endothelial19
and smooth muscle cells20 have been grown in vitro
on HYAFF constructs with the objective to develop
a new tissue engineered vascular substitute.
The HYAFF vascular graft tested in this experiment
showed the mechanical strength necessary to sustain
the arterial blood pressure in addition to the biochem-
ical property of slow biodegradability which allowed
for the full maturation of the neo-vessel before graft
degradation.
The absence of lymphocytes and neutrophils infil-
tration attested to the biocompatibility of the material.
Macroscopic and histological results confirmed the
ability of the prosthesis to create a ‘‘biomimetic’’Eur J Vasc Endovasc Surg Vol 32, October 2006
416 S. Lepidi et al.Fig. 4. 90 days after surgery. (A) HE staining of the neo-artery cross-section in the center. White areas represent biomaterial
remnants (black arrow). The hyaluronan is almost completely degraded and the adventitial tissue is fusing with the media.
(B) Magnification of the HE cross-section clearly showing the 3 layers of the neo-artery. vWF-positive endothelial cells
(C), MLCK-positive smooth muscle cells (C) and Weighert-stained elastic layers (D) are now well developed. Panel E shows
the nuclei staining (Hoechst). Scale bar¼ 500 mm.environment during tissue formation. The regener-
ated vessel grew inside the graft without signs of in-
filtration into the biomaterial wall.
During the postoperative period, rapid growth of
a confluent, adherent endothelial layer was observed,
most likely preventing acute thrombosis, since
thrombosis was never observed in our study. AfterEur J Vasc Endovasc Surg Vol 32, October 2006five days, the endothelial layer was evident along
the luminal surface. Participation of endothelial pro-
genitor cells (EPCs) in regenerative events was con-
firmed by the presence of CD34þ and VEGFR-2þ
cells. When regenerated vascular tissue growing from
the proximal and distal anastomotic sites joined at
the midline, cells lost CD34 expression and were
417Hyaluronan Biodegradable Scaffold for Small-caliber Artery Graftingpositive only for vWF, which is the typical marker of
mature endothelial cells. This indicated that the bio-
material surface promoted the anchoring of EPCs
to its surface, favouring the regeneration process.
The change of expression of endothelial cell-specific
marker from immature to mature could be also due
to shear stress. A recent study clearly demonstrates
how shear stress induces expression of mature endo-
thelial cell-specific markers and increase of functional
markers of the mature endothelial phenotype such as
uptake of ac-LDL and formation of tube-like struc-
tures on Matrigel.21
After 21 days, all vascular structures were present.
A layer of vascular smooth muscle cells and extracel-
lular matrix components, such as collagen and elastin,
were visible. After 90 days, the vascular structures
were well organized, resembling normal histological
features of an artery. Excessive tissue ingrowth and/
or intimal hyperplasia, which often occur at the anas-
tomotic points, were not observed. Absence of infiltra-
tion of the neo-vascular tissue into the biomaterial
wall indicated that the tubular graft promoted cell
proliferation and growth along its surfaces until tis-
sues joined at the midline. Biomaterial thickness
slowly degraded, permitting a gradual fusion be-
tween adventitial and inner layers.
In conclusion, the hyaluronic acid derived graft
used in the above described preliminary experimental
model seemed to fulfil the major requirements of a
microvascular scaffold,22 allowing a rapid vascular
tissue growth, facilitating rapid endothelialization of
the luminal surface, and withstanding pulsatile stress.
The findings of the present study are encouraging,
although limitations of the animal model used, like
the short length (1.5 mm) of the graft and the high-
flow aortic location require further animal models
using longer HYAFF grafts and more peripheral loca-
tions before translation of this new vascular conduit to
the clinical setting.
References
1 ISENBERG BC, WILLIAMS C, TRANQUILLO RT. Small-diameter artificial
arteries engineered in vitro. Circ Res 2006;98:25e35.
2 ZILLA P, DEUTSCH M, MEINHART J. Endothelial cell transplantation.
Semin Vasc Surg 1999;12:52e63.
3 WEINBERG CB, BELL E. A blood vessel model constructed
from collagen and cultured vascular cells. Science 1986;231:
397e400.
4 GREISLER HP, TATTERSALL CW, KLOSAK JJ, CABUSAO EA, GARFIELD JD,
KIM DU. Partially bioresorbable vascular grafts in dogs. Surgery
1991;110:645e654.5 L’HEUREUX N, PAQUET S, LABBE R, GERMAIN L, AUGER FA. A
completely biological tissue-engineered human blood vessel.
FASEB J 1998;12:47e56.
6 NIKLASON LE, GAO J, ABBOTT WM, HIRSCHI KK, HOUSER S, MARINI R
et al. Functional arteries grown in vitro. Science 1999;284:489e493.
7 WILSON GJ, COURTMAN DW. Acellular matrix: a biomaterials
approach. Ann Thorac Surg 1995;60:S353eS358.
8 SCHMITZ-RIXEN T, MEGERMAN J, COLVIN RB, WILLIAMS AM,
ABBOTT WM. Immunosuppressive treatment of aortic allografts.
J Vasc Surg 1988;7:82e92.
9 LEPIDI S, STERPETTI AV, CUCINA A, RANDONE B, PALUMBO R,
PATRIZI AL et al. The degree of porosity influences the release
of growth factors by healing polytetrafluoroethylene (PTFE)
grafts. Eur J Vasc Endovasc Surg 1996;11:36e41.
10 VESCOVO G, SCANNAPIECO G, SPANO` E, CALLIARI I, LEPROTTI C,
SERAFINI F et al. Myosin light chain kinase in vascular smooth
muscle. An immunohistochemical study in normotensive and
spontaneously hypertensive rats. BAM 1996;6:183e187.
11 WIGHT TN. Cell biology of arterial proteoglycans. Arteriosclerosis
1989;9:1e20.
12 DE REEDER EG, GIRARD N, POELMANN RE, VAN MUNSTEREN JC,
PATTERSON DF, GITTENBERGER-DE GROOT AC. Hyaluronic acid accu-
mulation and endothelial cell detachment in intimal thickening
of the vessel wall. The normal and genetically defective ductus
arteriosus. Am J Pathol 1988;132:574e585.
13 LEVESQUE H, GIRARD N, MAINGONNAT C, DELPECH A, CHAUZY C,
TAYOT J et al. Localization and solubilization of hyaluronan and
of the hyaluronan-binding protein hyaluronectin in human nor-
mal and arteriosclerotic arterial walls. Atherosclerosis 1994;105:
51e62.
14 RIESSEN R, WIGHT TN, PASTORE C, HENLEY C, ISNER JM. Distribution
of hyaluronan during extracellular matrix remodeling in human
restenotic arteries and balloon-injured rat carotid arteries.
Circulation 1996;93:1141e1147.
15 TONELLO C, ZAVAN B, CORTIVO R, BRUN P, PANFILO S, ABATANGELO G.
In vitro reconstruction of human dermal equivalent enriched
with endothelial cells. Biomaterials 2003;24:1205e1211.
16 CARAVAGGI C, DE GIGLIO R, PRITELLI C, SOMMARIA M, DALLA NOCE S,
FAGLIA E et al. HYAFF 11-based autologous dermal and epider-
mal grafts in the treatment of noninfected diabetic plantar and
dorsal foot ulcers: a prospective, multicenter, controlled, ran-
domized clinical trial. Diabetes Care 2003;26:2853e2859.
17 SOLCHAGA LA, DENNIS JE, GOLDBERG VM, CAPLAN AI. Hyaluronic
acid-based polymers as cell carriers for tissue-engineered repair
of bone and cartilage. J Orthop Res 1999;17:205e213.
18 LISIGNOLI G, FINI M, GIAVARESI G, NICOLI AN, TONEGUZZI S,
FACCHINI A. Osteogenesis of large segmental radius defects
enhanced by basic fibroblast growth factor activated bone mar-
row stromal cells grown on non-woven hyaluronic acid-based
polymer scaffold. Biomaterials 2002;23:1043e1051.
19 TURNER NJ, KIELTY CM, WALKER MG, CANFIELD AE. A novel
hyaluronan-based biomaterial (Hyaff-11) as a scaffold for endo-
thelial cells in tissue engineered vascular grafts. Biomaterials
2004;25:5955e5964.
20 REMUZZI A, MANTERO S, COLOMBO M, MORIGI M, BINDA E,
CAMOZZI D et al. Vascular smooth muscle cells on hyaluronic
acid: culture and mechanical characterization of an engineered
vascular construct. Tissue Eng 2004;10:699e710.
21 WANG H, RIHA GM, YAN S, LI M, CHAI H, YANG H et al. Shear
stress induces endothelial differentiation from a murine embry-
onic mesenchymal progenitor cell line. Arterioscler Thromb Vasc
Biol 2005;25:1817e1823.
22 MITCHELL SL, NIKLASON LE. Requirements for growing tissue-
engineered vascular grafts. Cardiovasc Pathol 2003;12:59e64.
Accepted 20 February 2006
Available online 5 May 2006Eur J Vasc Endovasc Surg Vol 32, October 2006
